
Kitov Pharma Ltd (KTOV) was up strongly in trading today due to news regarding one of its products. NT219, which is in a preclinical study, was found to demonstrate a strong anti-cancer effect. The new data revealed that even with a short exposure of cancerous cells to NT219, the drug was sufficient to trigger an irreversible shutdown of cancer pathways. As a result, significant interest in the stock was generated today, with volumes well over 50 million shares. Here’s a recap.